• Yasser M.Kz.
  • Abbas M. R.
  • Saba H.M.


Type 2diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by disorders of insulin action and insulin secretion, and associated with increase problem of insulin resistant. High plasma levels of insulin and glucose due to insulin resistance often lead tometabolic syndrome. Chronic inflammation associated with metabolic and immune system involves a network of cellular andsystemic responses that integrates many complex signaling pathways infiltration of inflammation cells in adipose tissue , abnormal pro-inflammatory cytokinesproduction(IL-8,TNF-α). The study is designed to measure glycosylated hemoglobin (HbA1c),IL-8 and TNF-α.These parameters and measures applied for thirty newly diagnosed  patients with diabetes before and after treatment divided into 3 group.Three groups of (10) patients each newly diagnosed withT2DM;group(1) receives:500mg metformin for 3 months with (HbA1c=9.54±1.95,IL-8=13.85±6.15,TNF-α=260.1±123.7).                                                      

group(2)receives:1000mg metformin for 3 months with (HbA1c=9.16±1.55,IL-8=15.02±6.28,TNF-α=230.86±49.26).    group(3)receives:1500mg metformin for 3 months with(HbA1c=9.80±1.94,IL-8=14.41±4.61,TNF-=207.42±40.45).                       

Blood samples were withdrawn from the patients at pretreatment,then after 3 months of treatment. After 3 months of  treatment, patient who received metformin 1500mg had greater reduction in  HbA1c,IL-8 and TNF-α(27,9percent,44.20percent and49.75percent respectively),compared with patient who received metformin 1000mg(18.3percent,15.77percent,34.42percent respectively)and to metformin 500mg(10.3percent.12.56percent and 4.72percent).

Metformin monotherapy are effective as an initial treatment of newly diagnosed diabetic patients in The national  diabetes center / University of Al-Mustansiriyah, Iraq.Metformin has significant reduction effect on these three group, had significant reduction in HbA1c and also significant reduction in cytokines in the three dose in different percent.



- The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999; 21: 617-621.

- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28(1): S37–42.

-Vijan, S "Type 2 diabetes". Annals of internal medicine (2010-03-02); 152 (5): ITC31–15.

- American Diabetes Association .Diagnosis and Classification of Diabetes mellitus. Diabetes Care 2008; 1 (1): S55-60.

-Wellen KE;Hotamisligil GS.; Inflammation, stress, and diabetes. J Clin Invest. 2005


-Black PH. ;The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med Hypotheses 2006; 67:879–91.

-Hotamisligil GS.; Inflammation and metabolic disorders. Nature 2006;444:860–7.

-Sag D.; Carling D.; Stout RD.;Suttles J.; Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol.2008;181:8633–8641.

-Bruun JM.; Pedersen SB.;Richelsen B .; Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm.Metab. Res.2000;32 :537–541 .

-T Lahousen, R E Roller, [...], and W J Schnedl. Silent haemoglobin variants and determination of HbA1c with the HPLC Bio-Rad Variant II. J. Clin. Pathol2002;55(9):699-703.

-Holman,R.R.;thorne K.I. ;Farmer A.J.; Daves M.J.; Keenan J.F.; Paul S.; and Levy J.C.Addtion of Biphasic,Prandial, or Basal Insulin to Oral Therapy in type 2 Diabetes. N.Engl. J. Med.2007; 357:1716-1730.

-American Association of Clinical Endocrinologists (AACE): Medical guidelines for clinical practice for the management of diabetes mellitus.Endocr.Pract.2007;13( 1) :3-68.

-Nathan DM.; Buse JB.; Davidson MB.; Ferrannini E.; Holman RR.; Sherwin R.;Zinman B.; Medical management of hyperglycemia in type 2 diabetes. a consensus algorithm for the initiation and adjustment of therapy. a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Diabetes Care 2009;32;193-203.

-Eleftheriadou I.; Grigoropoulou P.; Katsilambros N.; Tentolouris N.; The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.Curr. Diabetes Rev. 2008; 4: 340-356.

- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352(131);854-865.

-Inzucchi SE. Oralantihyperglycemic therapy for type 2 diabetes: scientific c review. JAMA 2002; 287 :360-372.

- Eriksson A.; Attvall S.; Bonnier M. et al. Short-term effects of metformin in type 2 diabetes.Diab.Obes.Metab.2007; 9:483-489.

- Dunn CJ.; Peters DH.; Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49721-749.

-Garber AJ.;Duncan TG.; Goodman al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose- response trial.Am J Med 1997; 102: 491-497.

- Pearson ER.; Donnelly LA.; Kimber C.; Whitley al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56: 2178-2182.

-Garber AJ.; Duncan TG.; Goodman AM.;et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose- response trial.AmJ Med 1997; 102: 491-497.

-Ronal, J., Koeing , charles , M . , Robert, L. et al .Synthesis of hemoglobins A1c in normal and diabetic mice: potential model of basement membrance thickening. PorocNatlAcad Sui USA. 1975; 72: 3687 -3691.

- Stefano Genovese .;Giorgia De Berardis .;Antonio Nicolucci.;EdoardoMannucci.;Virgilio Evangelista .;LiciaTotani.; Fabio Pellegrini.;Antonio Ceriello .Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes.Advances in Therapy 2013; 30 (2): 190-202.

-Pickup, J. C.; Chusney, G. D.; Thomas, S. M.; and Burt, D. ;Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000; 67(3): 291–300.

-Nappo, F., Esposito, K., Cioffi, M., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll.Cardiol. 2002; 39(7): 1145–1150.

-Ortega Martinez de Victoria, E., Xu, X., Koska, J., et al. Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes 2009;58(2): 385–393.

-Bastard, J.-P., Maachi, M., Lagathu, C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006;17(1): 4–12.

-Lavrenko AV.;Kutsenko LA, .;Solokhina IL.;Rasin MS.;KaÄ­dashevIP..;Efficacy of metformin as initial therapy in patients with coronary artery disease and diabetes type 2.LikSprava.2011;(1-2):89-95.

-Gómez-García; A., Martínez Torres G.; Ortega-Pierres; L. E.;Rodríguez-Ayala; E.;and Alvarez-Aguilar; C. [Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. Rev EspCardiol. 2007; 60(12): 1242–1249.

-Pruski; M.;Krysiak; R.; and Okopien; B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care2009 ;32(8): 1421–1424.

-Bruun JM;Pedersen SB;Richelsen B.Interleukin-8 production in human adipose tissue. inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin.HormMetab Res. 2000; 32(11-12): 537-41.

-Furuta; M; et al. Relationship of the tumor necrosis factor-alpha -308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2002;56: 141-145.

- Florez; JC.; Hirschhorn; J.; Altshuler.; D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet. 2003;4: 257-291.

- YoshiyukiHattori;Kunihiro Suzuki;Sachiko Hattori ;Kikuo Kasai .Metformin Inhibits Cytokine-Induced Nuclear Factor κB Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells. Hypertension 2006; 47 :1183-1188 .

-Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006 ;26(3):611-7.

-Notle MS;Karam JH. Pancreatic hormones and antidiabetic drugs. In

Katzung BG. Basic and Clinical Pharmacology. 11th edition. McGraw Hill.

Boston. 2009:p.741.

-Howland RD, Mycek MJ. (ed.).Lippincotts' Illustrated Reviews:

Pharmacology. (3rd ed.), Lippincott Williams& Wilkins, Philadelphia, 2006:p.289-292.



How to Cite

M.Kz., Y., M. R., A., & H.M., S. (2013). THE EFFECT OF METFORMIN 0N CYTOKINES IN IRAQI PATIENTS WITH TYPE 2 DIABETES. Innovare Journal of Medical Sciences, 1(3), 4–10. Retrieved from